Moderna Outperform Rating After 26.6% Flu Vaccine Efficacy and Hantavirus Success
Moderna received an Outperform upgrade after mRNA-1010 Phase 3 trial showed 26.6% efficacy overall and 27.4% in those 65+. Positive Phase 1 hantavirus data drove analyst price target increases by validating the mRNA platform’s versatility.
1. Wells Fargo Outperform Rating
Wells Fargo upgraded Moderna to an Outperform rating from Equal Weight following robust flu vaccine data, signaling confidence in the company’s growth prospects. The upgrade coincided with shares trading at $54.35.
2. Phase 3 Flu Vaccine Efficacy
Moderna’s seasonal flu vaccine candidate mRNA-1010 achieved 26.6% relative efficacy overall and 27.4% in adults aged 65 and older versus a standard-dose shot. The FDA PDUFA goal date for mRNA-1010 is set for August 5, with additional regulatory filings submitted in other regions.
3. Phase 1 Hantavirus Vaccine Data
Moderna’s Phase 1 hantavirus vaccine trial demonstrated strong immune responses and good tolerability across all dose levels. Following the data release, analysts raised their price targets, underscoring the platform’s adaptability for emerging viral threats.